Overview MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Status: Completed Trial end date: 2014-05-01 Target enrollment: Participant gender: Summary This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery. Phase: Phase 2 Details Lead Sponsor: National Cancer Institute (NCI)